Originally posted by gumboot
Great partner- but cheapish entry. No more Phase II funding worries when they get there. It's results now that matter as always
Great partner is right. THE LIFE BIOSCIENCES STORY
The only way to address the complexity of aging is by tackling each of the eight pathways that limit longevity and reduce healthspans.We have modeled our business accordingly by setting up individual Daughter companies to conduct their research independently and collaboratively. This itself is unprecedented. We are the first and largest company devoted to developing medicines for aging in its entirety. Each Daughter company was founded by the world’s leading scientists who work on the cutting-edge of aging research. Life Biosciences provides the capital, centralized management infrastructure and resources, acts as catalyst for ideas, insights and knowledge transfer, and provides advanced research facilities through its central lab in Cambridge, Mass. (USA).Another integral part of the Life Biosciences family is our technology company, Lua. Lua works to optimize the research of each Daughter company and enable Life Biosciences to derive critical data and insight across the organization. It is a leading HIPAA-compliant platform for patient-centric communication. Lua will allow for rapid data analysis and artificial intelligence (AI) capabilities to enable faster commercialization.Life Biosciences was co-founded in 2017 by David A. Sinclair, PhD, AO, a professor in the Department of Genetics at Harvard Medical School, and Tristan Edwards, an investment professional who developed its innovative company structure.THE STAKES COULD NOT BE HIGHERMillions of lives are being ended before their time. Productivity, joy and fulfillment are being cut short. The U.S. alone would save $4 trillion if people extended their heathspans and compressed the march of decline.
